Adagene Completes 60-Patient Enrollment in Randomized Phase 2 Muzastotug/KEYTRUDA Colorectal Trial
ADAG sits 54% above its 52-week low of $1.3.
Summary
Adagene finished enrolling all 60 patients in the randomized Phase 2 dose-optimization study of muzastotug plus Merck's KEYTRUDA in late-line MSS colorectal cancer without liver metastases. The trial randomizes 1:1 between two dosing regimens, with overall response rate as the primary endpoint and DOR, PFS and OS secondary. Initial results are expected in the first half of 2027 and will pick the dose for the Phase 3 registration trial, whose design the FDA already agreed to in 2025, including an OS primary endpoint and no monotherapy arm. The release also notes an additional equity investment from Sanofi tied to this trial, a modest but real endorsement of the program. For a micro-cap clinical-stage name, this is a genuine de-risking step on the lead asset, though the value-moving readout is still more than a year out. Watch for the 1H 2027 initial data, which determines whether the Phase 3 moves forward on schedule.
At the time of this announcement, ADAG was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $161.8M. The 52-week trading range was $1.30 to $4.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.